FDA Lifts Hold on Simufilam Phase 2a Study for TSC-Related Epilepsy

Filana Therapeutics announced the FDA has lifted the clinical hold on the simufilam IND, allowing the planned Phase 2a trial to begin screening in early 2027. This regulatory development is positive for FLNA's pipeline and potential to address a major unmet need.